Fig. 1 · Structure

Documents & Downloads

Tazarotene

Cat. No. A10894 CAS 118292-40-3
Tazarotene is a prodrug and a member of the acetylenic class of retinoids.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
COS-7 EC50 0.8 nM Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay [PMID: 19058965]
COS-7 EC50 40 nM Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay [PMID: 19058965]
COS-7 EC50 63 nM Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay [PMID: 19058965]

In Vitro Studies

In MSDi cells, Tazarotene produced a dose-dependent significant increase in ARSA activity, with a reported EC50 of 4.9 μM. Tazarotene also increased GALNS activity in MSDi cells, with a reported EC50 of 2 μM. In B16 TRCs treated with Tazarotene at 100 µm for 24 h, the reported apoptosis finding was that 30–50% of TRCs became apoptotic when treated with ATRA, tazarotene, or cisplatin. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Tazarotene increases ARSA activity in MSDi cells

Cell-based study · MSDi cells [1]

MSDi cells treated with Tazarotene for 3 days showed a dose-dependent significant increase in ARSA activity compared with DMSO-only treatment. The reported EC50 was 4.9 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ARSA activityARSA activity EC50 EC50 4.9 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
as low as 2 μM
Exposure duration
3 days
Method
applied to the cell culture medium
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Tazarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Tazarotene and bexarotene effectively increase the activity of lysosomal sulfatases in immortalized MSD patient cells (S16, S17); Materials and Methods > Drug treatment (S159, S162); Figure EV1 legend (S337)

ARSA activity: ARSA activity; comparator: DMSO‐only treatment — Results > Tazarotene and bexarotene effectively increase the activity of lysosomal sulfatases in immortalized MSD patient cells (S16, S17)

Apoptosis in Tazarotene-treated TRCs

Cell-based study · B16 TRCs [2]

B16 TRCs were treated with Tazarotene at 100 µm for 24 h. The reported result was that 30–50% of TRCs became apoptotic when treated with ATRA, tazarotene, or cisplatin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell apoptotic ratioapoptotic ratio 30–50% of TRCs became apoptotic[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 µm
Exposure duration
24 h
Reported limits
Not stated in the sentences used: route, vehicle, control.
Methods and source locations

Compound reported in the paper: Tazarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Retinoid WYC‐209 Is Highly Potent in Inducing TRC Apoptosis (S3); Figure 1 legend (S166)

cell apoptotic ratio: cell apoptotic ratio — Results > Retinoid WYC‐209 Is Highly Potent in Inducing TRC Apoptosis (S3); Figure 1 legend (S166)

Tazarotene increases GALNS activity in MSDi cells

Cell-based study · MSDi cells [1]

MSDi cells treated with Tazarotene at 5 μM for 3 days showed increased GALNS activity. The reported EC50 was 2 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GALNS activityGALNS activity EC50 EC50 2 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
3 days
Method
applied to the cell culture medium
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Tazarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Tazarotene and bexarotene effectively increase the activity of lysosomal sulfatases in immortalized MSD patient cells (S17); Materials and Methods > Drug treatment (S159, S162); Figure 1 legend (S295); Figure EV1 legend (S339)

GALNS activity: GALNS activity; comparator: DMSO‐only treatment — Results > Tazarotene and bexarotene effectively increase the activity of lysosomal sulfatases in immortalized MSD patient cells (S17)

In Vivo Studies

In NOD/SCID mice in the prevention group, oral Tazarotene starting on the day of tumor cell injection completely blocked palpable tumor appearance during the initial 6-week administration at 10 mg/kg, with a control group injected only with tumor cells serving as the comparison. After Tazarotene was stopped, previously impalpable allograft tumors became palpable and existing tumors grew larger. [3]

Palpable Tumor Suppression in Prevention Group Mice

Animal study · NOD/SCID mice; prevention group [3]

Six weeks of oral tazarotene completely blocked the appearance of palpable tumors in the prevention group. When oral tazarotene was stopped the previously non-palpable allograft tumors became palpable within two weeks, and the existing tumors grew larger.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
appearance of palpable tumorsReported result Initial 6-week administration of 10 mg/kg at 5 days per week: six weeks of oral tazarotene completely blocked the appearance of palpable tumors in the prevention group. We reduced the dose to 2 mg/kg and treated the mice for another 5 weeks. In the prevention group, 6 out of the 10 allografts remained impalpable until week 12, after tazarotene was stopped. When oral tazarotene was stopped the[3]

Conditions shared by the study groups

Route
oral gauvage
Treatment course
starting on the same day as the tumor cells were injected; initial 6-week administration; 5 days per week; another 5 weeks
Vehicle
100% ethanol; sunflower seed oil
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Tazarotene 10 mg/kg; 2 mg/kga control group injected only with tumor cellsInitial 6-week administration of 10 mg/kg at 5 days per week: six weeks of oral tazarotene completely blocked the appearance of palpable tumors in the prevention group. We reduced the dose to 2 mg/kg and treated the mice for another 5 weeks. In the prevention group, 6 out of the 10 allografts remained impalpable until week 12, after tazarotene was stopped. When oral tazarotene was stopped the previously non-palpable allograft tumors became palpable within two weeks, and the existing tumors grew larger.[3]
Tazarotene 10 mg/kg; 2 mg/kg
Model: NOD/SCID mice; prevention group
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: Tazarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Tazarotene inhibits BCC allograft growth (S29, S30, S31, S32, S35, S37); MATERIALS AND METHODS > Systemic administration of Tazarotene (S61, S62)

appearance of palpable tumors: appearance of palpable tumors; comparator: a control group injected only with tumor cells — RESULTS > Tazarotene inhibits BCC allograft growth (S30, S31, S32, S35, S37)

Tazarotene 10 mg/kg; 2 mg/kg · RESULTS > Tazarotene inhibits BCC allograft growth (S29, S30, S31, S32, S35, S37); MATERIALS AND METHODS > Systemic administration of Tazarotene (S62)

Specifications

Manufacturer Adooq Bioscience
CAS Number 118292-40-3
Formula C21H21NO2S
Molecular Weight 351.5
SMILES
CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 9 mg/mL (25.61 mM)
Water Insoluble
Ethanol 9 mg/mL (25.61 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Schlotawa L, Tyka K, Kettwig M, et al. Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency. EMBO Mol Med (2023). PMID: 36789546 DOI: 10.15252/emmm.202114837 Source material
  2. [2] Zhang Y, Dong Q, An Q, et al. Synthetic Retinoid Kills Drug-Resistant Cancer Stem Cells via Inducing RARγ-Translocation-Mediated Tension Reduction and Chromatin Decondensation. Adv Sci (Weinh) (2022). PMID: 36031407 DOI: 10.1002/advs.202203173 Source material
  3. [3] Wang GY, So PL, Wang L, et al. Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysis. J Invest Dermatol (2011). PMID: 21833014 DOI: 10.1038/jid.2011.204 Source material

Added to your cart

View Cart Checkout
Loading...